ArticleCancers2025

Real-World Outcomes of Chemoradiotherapy in Patients with Stage II/III Non-Small-Cell Lung Cancer in the Durvalumab Era: An Observational Study.

Jörg Andreas Müller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.